1
|
Bianchi E, Pata AP, Cantarini L, Frediani B, Gentileschi S. Upadacitinib and ustekinumab combination treatment for a refractory case of spondyloarthritis and Crohn's disease. Clin Exp Rheumatol 2023:20174. [PMID: 37812461 DOI: 10.55563/clinexprheumatol/qsy3kc] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 09/14/2023] [Indexed: 10/10/2023]
Affiliation(s)
- Elena Bianchi
- Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy
| | - Anna Paola Pata
- Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy
| | - Luca Cantarini
- Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy
| | - Bruno Frediani
- Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy
| | - Stefano Gentileschi
- Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy.
| |
Collapse
|
2
|
Credi C, Dallari C, Nocentini S, Gatta G, Bianchi E, Wiersma DS, Pavone FS. Fiber-Based SERS-Fluidic Polymeric Platforms for Improved Optical Analysis of Liquids. Bioengineering (Basel) 2023; 10:676. [PMID: 37370607 DOI: 10.3390/bioengineering10060676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 05/23/2023] [Accepted: 05/25/2023] [Indexed: 06/29/2023] Open
Abstract
Downsizing surface-enhanced Raman spectroscopy (SERS) within microfluidic devices has opened interesting perspectives for the development of low-cost and portable (bio)sensors for the optical analysis of liquid samples. Despite the research efforts, SERS-fluidic devices still rely either on the use of expensive bulky set-ups or on polymeric devices giving spurious background signals fabricated via expensive manufacturing processes. Here, polymeric platforms integrating fluidics and optics were fabricated with versatile designs allowing easy coupling with fiber-based Raman systems. For the first time, anti-fouling photocurable perfluoropolyether (PFPE) was explored for high-throughput SERS-integrating chip fabrication via replica molding of negative stamps obtained through standard and advanced fabrication processes. The PFPE devices comprised networks of channels for fluid handling and for optical fiber housing with multiple orientations. Embedded microfeatures were used to control the relative positioning of the fibers, thus guaranteeing the highest signal delivering and collection. The feasibility of PFPE devices as fiber-based SERS fluidic platforms was demonstrated through the straightforward acquisition of Raman-SERS spectra of a mixture of gold nanoparticles as SERS substrates with rhodamine 6G (Rh6G) at decreasing concentrations. In the presence of high-performing gold nanostars, the Rh6G signal was detectable at dilutions down to the nanomolar level even without tight focusing and working at low laser power-a key aspect for analyte detection in real-world biomedical and environmental applications.
Collapse
Affiliation(s)
- Caterina Credi
- European Laboratory for Non-Linear Spectroscopy (LENS), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy
- National Institute of Optics, National Research Council (INO-CNR), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy
| | - Caterina Dallari
- European Laboratory for Non-Linear Spectroscopy (LENS), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy
- Department of Physics, University of Florence, Via G. Sansone 1, 50019 Sesto Fiorentino, Italy
| | - Sara Nocentini
- European Laboratory for Non-Linear Spectroscopy (LENS), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy
- National Institute of Optics, National Research Council (INO-CNR), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy
- National Institute of Metrology (INRiM), 10135 Turin, Italy
| | - Gabriele Gatta
- European Laboratory for Non-Linear Spectroscopy (LENS), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy
| | - Elena Bianchi
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy
| | - Diederik S Wiersma
- European Laboratory for Non-Linear Spectroscopy (LENS), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy
- Department of Physics, University of Florence, Via G. Sansone 1, 50019 Sesto Fiorentino, Italy
- National Institute of Metrology (INRiM), 10135 Turin, Italy
| | - Francesco S Pavone
- European Laboratory for Non-Linear Spectroscopy (LENS), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy
- National Institute of Optics, National Research Council (INO-CNR), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy
- Department of Physics, University of Florence, Via G. Sansone 1, 50019 Sesto Fiorentino, Italy
| |
Collapse
|
3
|
Ruberti A, Kremer Hovinga JA, Nappi F, Vettese A, Bianchi E, Fernandes E, Galfetti E, Monotti R, Paul P, Regazzoni S, Valente D, Rossi D, Stussi G, Gerber B. Acquired haemophilia A in southern Switzerland from 2013 to 2019: a case series. Swiss Med Wkly 2023; 153:40048. [PMID: 37021783 DOI: 10.57187/smw.2023.40048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
Abstract
AIMS OF THE STUDY: Acquired haemophilia A is a rare disease with an annual incidence of 1.48 per million. Based on clinical observations, we suspect a higher incidence in southern Switzerland, and aimed at providing local epidemiological data, and clinical information regarding diagnosis, treatment and outcome in our region.
METHODS: All adult patients with acquired haemophilia A treated between 2013 and 2019 in our facility were included in the present retrospective analysis.
RESULTS: We treated 11 patients with acquired haemophilia A between 2013 and 2019, resulting in an annual incidence of 4.5 per million (95% confidence interval [CI] 0–9.0). Median delay from first symptoms to diagnosis was 4.5 days, and the median age at diagnosis was 79 years (range 23–87). Possible causative conditions were: pregnancy (n = 1), polyarteritis nodosa (n = 1), myelodysplastic syndrome (n = 1), chronic human immunodeficiency virus (HIV) (n = 1), and HIV postexposure prophylaxis (n = 1). In five patients no underlying or associated condition was identified. Median activated partial thromboplastin time (aPTT)) at baseline was 79 seconds (65–117; ref. value <38 sec), and FVIII:C 2.15% (<1–3.75%). A FVIII:C <1% was present in 4/10 patients. Median FVIII-inhibitor titre was 10.3 BU/ml (2.4–75.0 BU/ml). All patients had bleeding symptoms, 5/10 patients had major bleedings, and 7/10 patients were treated with bypassing agents. All patients received corticosteroids; 7/10 patients received immunosuppressive combination therapy. FVIII levels of ≥50% were achieved after a median of 40 days (8–62). One patient had a severe immunosuppressive therapy-related infection. An 87-years-old woman died for reasons not related to acquired haemophilia A or immunosuppressive therapy.
CONCLUSIONS: Acquired haemophilia A is a rare disease, but manageable despite the advanced patient age and comorbidities. Its incidence in Southern Switzerland is higher than previously suspected.
Collapse
Affiliation(s)
- Andrea Ruberti
- Department of Internal Medicine, Ospedale La Carità, Locarno, Switzerland
- Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland
| | - Johanna A Kremer Hovinga
- Department of Haematology and Central Haematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland
| | - Federico Nappi
- Department of Internal Medicine, Ospedale La Carità, Locarno, Switzerland
| | - Aurora Vettese
- Department of Laboratory Medicine EOLAB, Bellinzona, Switzerland
| | - Elena Bianchi
- Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Eliana Fernandes
- Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Elena Galfetti
- Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Rita Monotti
- Department of Internal Medicine, Ospedale La Carità, Locarno, Switzerland
| | - Pamella Paul
- Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Stefano Regazzoni
- Department of Internal Medicine, Ospedale Civico, Lugano, Switzerland
| | | | - Davide Rossi
- Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- Laboratory of Experimental Haematology, Institute of Oncology Research, Bellinzona, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - Georg Stussi
- Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - Bernhard Gerber
- Department of Laboratory Medicine EOLAB, Bellinzona, Switzerland
- Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- University of Zurich, Switzerland
| |
Collapse
|
4
|
Rocha ALV, Silva PL, Nishio SSA, Carnetta CA, Frizarini PC, Moraes MPT, Bianchi E, Deffune E. ANÁLISE IN VIVO DA AÇÃO DO SECRETOMA DE CÉLULAS TRONCO MESENQUIMAIS NA REGULAÇÃO DO PROCESSO DE PRODUÇÃO DE ANTICORPOS. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
5
|
Corvaro M, Johnson K, Himmelstein M, Bianchi E, Mingoia R, Bartels M, Reiss R, Terry C, LaRocca J, Murphy L, Gehen S. P06-13 Spinosad – mode of action and human relevance assessment of dystocia in rats. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
De Stefano P, Bianchi E, Dubini G. The impact of microfluidics in high-throughput drug-screening applications. Biomicrofluidics 2022; 16:031501. [PMID: 35646223 PMCID: PMC9142169 DOI: 10.1063/5.0087294] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 05/02/2022] [Indexed: 05/05/2023]
Abstract
Drug discovery is an expensive and lengthy process. Among the different phases, drug discovery and preclinical trials play an important role as only 5-10 of all drugs that begin preclinical tests proceed to clinical trials. Indeed, current high-throughput screening technologies are very expensive, as they are unable to dispense small liquid volumes in an accurate and quick way. Moreover, despite being simple and fast, drug screening assays are usually performed under static conditions, thus failing to recapitulate tissue-specific architecture and biomechanical cues present in vivo even in the case of 3D models. On the contrary, microfluidics might offer a more rapid and cost-effective alternative. Although considered incompatible with high-throughput systems for years, technological advancements have demonstrated how this gap is rapidly reducing. In this Review, we want to further outline the role of microfluidics in high-throughput drug screening applications by looking at the multiple strategies for cell seeding, compartmentalization, continuous flow, stimuli administration (e.g., drug gradients or shear stresses), and single-cell analyses.
Collapse
Affiliation(s)
- Paola De Stefano
- Laboratory of Biological Structure Mechanics, Department of Chemistry, Materials and Chemical Engineering “G. Natta,” Politecnico di Milano, Italy
| | - Elena Bianchi
- Laboratory of Biological Structure Mechanics, Department of Chemistry, Materials and Chemical Engineering “G. Natta,” Politecnico di Milano, Italy
| | - Gabriele Dubini
- Laboratory of Biological Structure Mechanics, Department of Chemistry, Materials and Chemical Engineering “G. Natta,” Politecnico di Milano, Italy
| |
Collapse
|
7
|
Halstead SK, Gourlay DS, Penderis J, Bianchi E, Dondi M, Wessmann A, Musteata M, Le Chevoir M, Martinez-Anton L, Bhatti SFM, Volk H, Mateo I, Tipold A, Ives E, Pakozdy A, Gutierrez-Quintana R, Brocal J, Whitehead Z, Granger N, Pazzi P, Harcourt-Brown T, José-López R, Rupp S, Schenk HC, Smith P, Gandini G, Menchetti M, Mortera-Balsa V, Rusbridge C, Tauro A, Cozzi F, Deutschland M, Tirrito F, Freeman P, Lowrie M, Jackson MR, Willison HJ, Rupp A. Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis. J Small Anim Pract 2022; 63:104-112. [PMID: 34791652 DOI: 10.1111/jsap.13439] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 08/13/2021] [Accepted: 09/19/2021] [Indexed: 11/29/2022]
Abstract
OBJECTIVES A previous single-country pilot study indicated serum anti-GM2 and anti-GA1 anti-glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort. MATERIALS AND METHODS Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti-glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti-glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis. RESULTS Anti-GM2 anti-glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti-GalNAc-GD1a anti-glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti-glycolipid antibodies were frequently present concomitantly. Anti-GA1 anti-glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti-GM2 and anti-GalNAc-GD1a anti-glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (1.27 to 5.31) and 3.00 (1.22 to 7.89), respectively. Anti-GalNAc-GD1a anti-glycolipid antibodies were more commonly observed in dogs unable to walk (OR 4.56, 1.56 to 14.87). CLINICAL SIGNIFICANCE Anti-GM2 and anti-GalNAc-GD1a immunoglobulin G anti-glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis.
Collapse
Affiliation(s)
- S K Halstead
- Neuroimmunology Laboratory, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, G12 8TA, UK
| | - D S Gourlay
- Neuroimmunology Laboratory, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, G12 8TA, UK
| | - J Penderis
- Vet Extra Neurology, Broadleys Veterinary Hospital, Stirling, FK7 7LE, UK
| | - E Bianchi
- Department of Veterinary Science, University of Parma, 43126, Parma, Italy
| | - M Dondi
- Department of Veterinary Science, University of Parma, 43126, Parma, Italy
| | - A Wessmann
- Neurology and Neurosurgery Service, Pride Veterinary Centre, Pride Park, Derby, DE24 8HX, UK
| | - M Musteata
- Neurology Service, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Iași, 700489, Romania
| | - M Le Chevoir
- Department of Neurology and Neurosurgery, University of Melbourne, Werribee, Victoria, 3030, Australia
| | - L Martinez-Anton
- Chestergates Veterinary Specialists, Telford Court, Chestergates, CH1 6LT, UK
| | - S F M Bhatti
- Small Animal Department, Small Animal Teaching Hospital, Faculty of Veterinary Medicine, Ghent University, 9820, Merelbeke, Belgium
| | - H Volk
- Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30559, Hannover, Germany
| | - I Mateo
- Servicio de Neurología, Hospital Clínico Veterinario - Universidad Alfonso X el Sabio, Madrid, Spain
| | - A Tipold
- Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30559, Hannover, Germany
| | - E Ives
- Anderson Moores Veterinary Specialists, Hursley, Winchester, SO21 2LL, UK
| | - A Pakozdy
- University Hospital for Small Animals, University of Veterinary Medicine, Vienna, Austria
| | | | - J Brocal
- Wear Referrals Veterinary Hospital, Bradbury, Stockton-on-Tees, TS21 2ES, UK
| | - Z Whitehead
- Department of Companion Animal Clinical Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, 0110, South Africa
| | - N Granger
- The Royal Veterinary College, University of London, Hatfield, Hertfordshire, UK.,CVS Referrals, Bristol Veterinary Specialists at Highcroft, Bristol, UK
| | - P Pazzi
- Department of Companion Animal Clinical Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, 0110, South Africa
| | - T Harcourt-Brown
- Langford Veterinary Services, School of Veterinary Sciences, University of Bristol, Lower Langford, BS40 5DU, UK
| | - R José-López
- School of Veterinary Medicine, University of Glasgow, Glasgow, G61 1QH, UK
| | - S Rupp
- Tierklinik Hofheim, 65719, Hofheim, Germany
| | - H C Schenk
- Tierklinik Lüneburg, 21337, Lüneburg, Germany
| | - P Smith
- Hamilton Specialist Referrals, Cressex Business Park, High Wycombe, HP12 3SD, UK
| | - G Gandini
- Department of Veterinary Medical Sciences, University of Bologna, 40064, Ozzano dell'Emilia, Italy
| | - M Menchetti
- Neurology and Neurosurgery Division, San Marco Veterinary Clinic, Veggiano, Italy
| | - V Mortera-Balsa
- North Downs Specialist Referrals, 3&4 The Brewerstreet Dairy Business Park, Bletchingley, Surrey, RH1 4QP, UK
| | - C Rusbridge
- Neurology Section, Fitzpatrick Referrals, Godalming, Surrey, GU2 7AL, UK.,School of Veterinary Medicine, Faculty of Health & Medical Sciences, University of Surrey, Guildford, Surrey, GU2 7AL, UK
| | - A Tauro
- Chestergates Veterinary Specialists, Telford Court, Chestergates, CH1 6LT, UK
| | - F Cozzi
- Clinica Neurologica Veterinaria, 20148, Milan, Italy
| | | | - F Tirrito
- Clinica Neurologica Veterinaria, 20148, Milan, Italy
| | - P Freeman
- The Queen's Veterinary School Hospital, Cambridge, CB3 0ES, UK
| | - M Lowrie
- Dovecote Veterinary Hospital, Castle Donington, Derby, DE74 2LJ, UK
| | - M R Jackson
- Institute of Cancer Sciences, University of Glasgow, Bearsden, G61 1QH, UK
| | - H J Willison
- Neuroimmunology Laboratory, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, G12 8TA, UK
| | - A Rupp
- School of Veterinary Medicine, University of Glasgow, Glasgow, G61 1QH, UK
| |
Collapse
|
8
|
Gangeri L, Alfieri S, Scrignaro M, Brunellia C, Bianchi E, Bosisio M, Zoncheddu P, Ferri F, Biffa G, Parks-Vernizzi E, Bredle J, Borreani C. Development of the Functional Assessment of Chronic Illness Therapy - Liver Transplant (FACT-LT) Scale. Int J Organ Transplant Med 2022; 13:28-35. [PMID: 37383419 PMCID: PMC10294034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/30/2023] Open
Abstract
Background This study aims to propose an initial development of the FACT-Liver Transplant (FACT-LT) scale to assess the major physical and emotional concerns of patients before and after Orthotopic Liver transplant (OLT) due to acute and chronic liver failure and hepatocellular carcinoma. Methods The FACT-LT was developed in two phases. In Phase I, items were generated: 1) through interviews with 10 OLT experts and 15 candidates for or recipients of both oncological and non-oncological OLT which identified relevant topics; 2) from the FACIT item bank. In Phase II, a questionnaire to assess item frequency, applicability, and comprehension was administered to 20 OLT experts and, to assess item difficulty, embarrassment and content irrelevance, to 30 transplant recipients or candidate patients (15 oncological, 15 non-oncological). Results In Phase I, 44 items were formulated/reviewed, and 30 items were maintained. All the healthcare professionals interviewed rejected the recommendation to develop two different modules for cancer and non-cancer patients. In Phase II, the majority of the experts and patients expressed an overall satisfaction with the questionnaire, indicating that the items were relevant, comprehensible and not embarrassing (range 75% - 99%). The first version of the FACT-LT includes 28 items defining four QOL domains: 5 items relating to Physical Well-Being, 8 to Functional Well-Being, 13 to Emotional Well-Being, and 2 to Social/Family Well-Being. Conclusion The preliminary results obtained were promising; however further studies are needed, in order to proceed with a FACT-LT validation process.
Collapse
Affiliation(s)
- L Gangeri
- Clinical Psychology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Alfieri
- Clinical Psychology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Scrignaro
- Clinical Psychology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - C Brunellia
- Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E Bianchi
- Clinical Psychology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Bosisio
- Clinical Psychology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | | - F Ferri
- Coordinamento Regionale Trapianti Lombardia c/o Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
| | - G Biffa
- IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | | | - J Bredle
- FACITtrans, Ponte Vedra, FL, USA
| | - C Borreani
- Clinical Psychology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
9
|
De Stefano P, Briatico-Vangosa F, Bianchi E, Pellegata AF, Hartung de Hartungen A, Corti P, Dubini G. Bioprinting of Matrigel Scaffolds for Cancer Research. Polymers (Basel) 2021; 13:2026. [PMID: 34205767 PMCID: PMC8233772 DOI: 10.3390/polym13122026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2021] [Revised: 05/30/2021] [Accepted: 06/16/2021] [Indexed: 12/24/2022] Open
Abstract
Cancer is one of the most life-threatening diseases worldwide. Despite the huge efforts, the failure rate of therapies remains high due to cells heterogeneity, so physiologically relevant models are strictly necessary. Bioprinting is a technology able to form highly complex 3D tissue models and enables the creation of large-scale constructs. In cancer research, Matrigel® is the most widely used matrix, but it is hardly bioprinted pure, without the use of any other bioink as reinforcement. Its complex rheological behavior makes the control with a standard bioprinting process nearly impossible. In this work, we present a customized bioprinting strategy to produce pure Matrigel® scaffolds with good shape fidelity. To this aim, we realized a custom-made volumetric dispensing system and performed printability evaluations. To determine optimal printing parameters, we analyzed fibers spreading ratio on simple serpentines. After identifying an optimal flow rate of 86.68 ± 5.77 µL/min and a printing speed of 10 mm/min, we moved forward to evaluate printing accuracy, structural integrity and other key parameters on single and multi-layer grids. Results demonstrated that Matrigel® was able to maintain its structure in both simple and complex designs, as well as in single and multilayer structures, even if it does not possess high mechanical strength. In conclusion, the use of volumetric dispensing allowed printing pure Matrigel® constructs with a certain degree of shape fidelity on both single and multiple layers.
Collapse
Affiliation(s)
- Paola De Stefano
- Laboratory of Biological Structure Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy; (E.B.); (A.F.P.); (A.H.d.H.); (P.C.); (G.D.)
| | - Francesco Briatico-Vangosa
- Polymer Engineering Group, Department of Chemistry, Materials and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy;
| | - Elena Bianchi
- Laboratory of Biological Structure Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy; (E.B.); (A.F.P.); (A.H.d.H.); (P.C.); (G.D.)
| | - Alessandro Filippo Pellegata
- Laboratory of Biological Structure Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy; (E.B.); (A.F.P.); (A.H.d.H.); (P.C.); (G.D.)
| | - Ariel Hartung de Hartungen
- Laboratory of Biological Structure Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy; (E.B.); (A.F.P.); (A.H.d.H.); (P.C.); (G.D.)
| | - Pietro Corti
- Laboratory of Biological Structure Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy; (E.B.); (A.F.P.); (A.H.d.H.); (P.C.); (G.D.)
| | - Gabriele Dubini
- Laboratory of Biological Structure Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy; (E.B.); (A.F.P.); (A.H.d.H.); (P.C.); (G.D.)
| |
Collapse
|
10
|
Martin DH, Bianchi E, Ben Mustapha S, Frères P. [Glioblastoma]. Rev Med Liege 2021; 76:419-424. [PMID: 34080374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Glioblastoma is the most common primary malignant brain tumor. Despite treatments combining excisional surgery, chemotherapy, and radiotherapy, overall survival remains low and the incidence of tumor recurrence remains high. Advances in the understanding of the disease, particularly its molecular biology and the mechanisms of action of systemic and radiotherapeutic treatments, as well as the development of image-guided surgical techniques, offer hope for the control of this hitherto incurable disease.
Collapse
Affiliation(s)
- D H Martin
- Service de Neurochirurgie, CHU Liège, Belgique
| | - E Bianchi
- Service d'Anatomie et Cytologie pathologiques, CHU Liège, Belgique
| | | | - P Frères
- Service d'Oncologie médicale, CHU Liège, Belgique
| |
Collapse
|
11
|
Mainardi VL, Arrigoni C, Bianchi E, Talò G, Delcogliano M, Candrian C, Dubini G, Levi M, Moretti M. Improving cell seeding efficiency through modification of fiber geometry in 3D printed scaffolds. Biofabrication 2021; 13. [PMID: 33578401 DOI: 10.1088/1758-5090/abe5b4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 02/12/2021] [Indexed: 11/11/2022]
Abstract
Cell seeding on 3D scaffolds is a very delicate step in tissue engineering applications, influencing the outcome of the subsequent culture phase, and determining the results of the entire experiment. Thus, it is crucial to maximize its efficiency. To this purpose, a detailed study of the influence of the geometry of the scaffold fibers on dynamic seeding efficiency is presented. 3D printing technology was used to realize PLA porous scaffolds, formed by fibers with a non-circular cross-sectional geometry, named multilobed to highlight the presence of niches and ridges. An oscillating perfusion bioreactor was used to perform bidirectional dynamic seeding of MG63 cells. The fiber shape influences the fluid dynamic parameters of the flow, affecting values of fluid velocity and wall shear stress. The path followed by cells through the scaffold fibers is also affected and results in a larger number of adhered cells in multilobed scaffolds compared to scaffolds with standard pseudo cylindrical fibers. Geometrical and fluid dynamic features can also have an influence on the morphology of adhered cells. The obtained results suggest that the reciprocal influence of geometrical and fluid dynamic features and their combined effect on cell trajectories should be considered to improve the dynamic seeding efficiency when designing scaffold architecture.
Collapse
Affiliation(s)
- Valerio Luca Mainardi
- Regenerative Medicine Technologies Lab, Ente Ospedaliero Cantonale, Via Tesserete, 46, Lugano, 6900, SWITZERLAND
| | - Chiara Arrigoni
- Regenerative Medicine Technologies Lab, Ente Ospedaliero Cantonale, Via Tesserete, 46, Lugano, 6900, SWITZERLAND
| | - Elena Bianchi
- Department of Chemistry, Materials and Chemical Engineering "Giulio Natta", Politecnico di Milano, Piazza Leonardo da Vinci, 32, Milano, 20133, ITALY
| | - Giuseppe Talò
- Cell and Tissue Engineering Lab, IRCCS Istituto Ortopedico Galeazzi, Via Riccardo Galeazzi, 4, Milano, 20161, ITALY
| | - Marco Delcogliano
- Unità di Traumatologia e Ortopedia, Ente Ospedaliero Cantonale, Via Tesserete, 46, Lugano, 6900, SWITZERLAND
| | - Christian Candrian
- Unità di Traumatologia e Ortopedia, Ente Ospedaliero Cantonale, Via Tesserete, 46, Lugano, 6900, SWITZERLAND
| | - Gabriele Dubini
- Department of Chemistry, Materials and Chemical Engineering "Giulio Natta", Politecnico di Milano, Piazza Leonardo da Vinci, 32, Milano, 20133, ITALY
| | - Marinella Levi
- Department of Chemistry, Materials and Chemical Engineering "Giulio Natta", Politecnico di Milano, Piazza Leonardo da Vinci, 32, Milano, 20133, ITALY
| | - Matteo Moretti
- Regenerative Medicine Technologies Laboratory, Ente Ospedaliero Cantonale, Via Tesserete, 46, Lugano, 6900, SWITZERLAND
| |
Collapse
|
12
|
Atzeni C, Lesma G, Dubini G, Masi M, Rossi F, Bianchi E. Computational fluid dynamic models as tools to predict aerosol distribution in tracheobronchial airways. Sci Rep 2021; 11:1109. [PMID: 33441807 PMCID: PMC7806585 DOI: 10.1038/s41598-020-80241-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Accepted: 12/16/2020] [Indexed: 01/29/2023] Open
Abstract
Aerosol and pollutants, in form of particulates 5-8 μm in main size face every day our respiratory system as natural suspension in air or forced to be inhaled as a coadjutant in a medical therapy for respiratory diseases. This inhalation happens in children to elderly, women and men, healthy or sick and disable people. In this paper we analyzed the inhalation of aerosol in conditions assimilable to the thermal therapy. We use a computational fluid dynamic 3D model to compute and visualize the trajectories of aerosol (3-7-10-25 µm) down to the sixth generation of bronchi, in a steady and dynamic condition (7 µm) set as breath cycle at rest. Results, compared to a set of milestone experimental studies published in literature, allow the comprehension of particles behavior during the inhalation from mouth to bronchi sixth generation, the visualization of jet at larynx constriction and vortices, in an averaged characteristic rigorous geometrical model including tracheal rings. Results on trajectories and deposition show the importance of the including transient physiological breath cycle on aerosol deposition analyses. Numerical and graphical results, may enable the design of medical devices and protocols to make the inhalations more effective in all the users' population.
Collapse
Affiliation(s)
- Claudia Atzeni
- grid.4643.50000 0004 1937 0327Laboratory of Biological Structures Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering “Giulio Natta”, Politecnico Di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy
| | - Gianluca Lesma
- grid.4643.50000 0004 1937 0327Laboratory of Biological Structures Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering “Giulio Natta”, Politecnico Di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy
| | - Gabriele Dubini
- grid.4643.50000 0004 1937 0327Laboratory of Biological Structures Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering “Giulio Natta”, Politecnico Di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy
| | - Maurizio Masi
- grid.4643.50000 0004 1937 0327Department of Chemistry, Materials and Chemical Engineering “Giulio Natta”, Politecnico Di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy
| | - Filippo Rossi
- grid.4643.50000 0004 1937 0327Department of Chemistry, Materials and Chemical Engineering “Giulio Natta”, Politecnico Di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy
| | - Elena Bianchi
- grid.4643.50000 0004 1937 0327Laboratory of Biological Structures Mechanics (LaBS), Department of Chemistry, Materials and Chemical Engineering “Giulio Natta”, Politecnico Di Milano, Piazza Leonardo da Vinci 32, 20133 Milan, Italy
| |
Collapse
|
13
|
von Oertzen TJ, Macerollo A, Leone MA, Beghi E, Crean M, Oztuk S, Bassetti C, Twardzik A, Bereczki D, Di Liberto G, Helbok R, Oreja‐ Guevara C, Pisani A, Sauerbier A, Sellner J, Soffietti R, Zedde M, Bianchi E, Bodini B, Cavallieri F, Campiglio L, Maia LF, Priori A, Rakusa M, Taba P, Moro E, Jenkins TM. EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic. Eur J Neurol 2021; 28:7-14. [PMID: 33058321 PMCID: PMC7675361 DOI: 10.1111/ene.14521] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 08/20/2020] [Accepted: 08/31/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND AND PURPOSE The recent SARS-CoV-2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast-evolving pandemic, evidence-based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID-19. METHODS A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP co-chairs rated importance on a five-point Likert scale. Results were graded by importance and reported as consensus statements. RESULTS In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fifty-nine statements obtained >70% agreement and were retained. In round three, responses were received from 55 co-chairs of 29 SPs. Whilst general recommendations related to prevention of COVID-19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy. CONCLUSION This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID-19 pandemic that provides immediate guidance for neurologists. In this fast-evolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges.
Collapse
Affiliation(s)
- T. J. von Oertzen
- Faculty of MedicineJohannes‐Kepler UniversitätLinzAustria
- Department of Neurology 1Kepler UniversitätsklinikumLinzAustria
| | - A. Macerollo
- Walton Centre NHS Foundation TrustLiverpoolUK
- Faculty of Health and Life SciencesUniversity of LiverpoolLiverpoolUK
| | - M. A. Leone
- UO NeurologiaFondazione IRCCS 'Casa Sollievo della Sofferenza'San Giovanni RotondoItaly
| | - E. Beghi
- Department of NeuroscienceIstituto di Ricerche Farmacologiche Mario Negri IRCCSMilanItaly
| | - M. Crean
- European Academy of NeurologyHead OfficeViennaAustria
| | - S. Oztuk
- Department of NeurologyFaculty of MedicineSelcuk UniversityKonyaTurkey
| | - C. Bassetti
- Department of NeurologyInselspitalUniversity of BernBernSwitzerland
| | - A. Twardzik
- European Academy of NeurologyHead OfficeViennaAustria
| | - D. Bereczki
- Department of NeurologySemmelweis UniversityBudapestHungary
| | - G. Di Liberto
- Department of Pathology and ImmunologyGeneva Faculty of MedicineGenevaSwitzerland
| | - R. Helbok
- Department of NeurologyMedical University of InnsbruckInnsbruckAustria
| | - C. Oreja‐ Guevara
- Department of NeurologyHospital Clínico San CarlosMadridSpain
- Departamento de MedicinaFacultad de MedicinaUniversidad Complutense de Madrid (UCM)MadridSpain
- IdISSCMadridSpain
| | - A. Pisani
- NeurologyDepartment of Systems MedicineUniversity of Rome Tor VergataRomeItaly
| | - A. Sauerbier
- Department of NeurologyUniversity Hospital CologneCologneGermany
| | - J. Sellner
- Department of NeurologyLandesklinikum Mistelbach‐GänserndorfMistelbachAustria
- Department of NeurologyChristian Doppler Medical CenterParacelsus Medical UniversitySalzburgAustria
- Department of NeurologyKlinikum rechts der IsarTechnische Universität MünchenMünchenGermany
| | - R. Soffietti
- Division of Neuro‐OncologyDepartment of NeuroscienceUniversity of TurinTurinItaly
| | - M. Zedde
- Neurology UnitNeuromotor and Rehabilitation DepartmentAzienda USL‐IRCCS di Reggio EmiliaReggio EmiliaItaly
| | - E. Bianchi
- Department of NeuroscienceIstituto di Ricerche Farmacologiche Mario Negri IRCCSMilanItaly
| | - B. Bodini
- Department of NeurologySaint‐Antoine HospitalAPHPSorbonne UniversityParisFrance
| | - F. Cavallieri
- Neurology UnitNeuromotor and Rehabilitation DepartmentAzienda USL‐IRCCS di Reggio EmiliaReggio EmiliaItaly
- Clinical and Experimental Medicine PhD ProgramUniversity of Modena and Reggio EmiliaReggio EmiliaItaly
| | - L. Campiglio
- Division of Neurology'Aldo Ravelli' Research CenterDepartment of NeurologyUniversity of Milan and ASST Santi Paolo e CarloMilanItaly
| | - L. F. Maia
- Department of NeurologyCentro Hospitalar Universitário do PortoPortoPortugal
| | - A. Priori
- Division of Neurology'Aldo Ravelli' Research CenterDepartment of NeurologyUniversity of Milan and ASST Santi Paolo e CarloMilanItaly
| | - M. Rakusa
- Department of NeurologyUniversity Medical Centre MariborMariborSlovenia
| | - P. Taba
- Department of Neurology and NeurosurgeryInstitute of Clinical MedicineUniversity of TartuTartuEstonia
| | - E. Moro
- Division of NeurologyCHU of GrenobleGrenoble Alpes UniversityGrenoble Institute of NeurosciencesGrenobleFrance
| | - T. M. Jenkins
- Sheffield Institute for Translational NeuroscienceUniversity of SheffieldSheffieldUK
- Sheffield Teaching Hospitals NHS Foundation TrustSheffieldUK
| | | |
Collapse
|
14
|
Stendardo M, Maietti E, Masotti E, Bianchi E, Manfredini R, Boschetto P. Sleep quality: a critical determinant of perceived quality of life in the administrative-technical workers of an Italian university. Eur Rev Med Pharmacol Sci 2020; 24:13025-13036. [PMID: 33378054 DOI: 10.26355/eurrev_202012_24208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
OBJECTIVE This observational study aims to analyze the quality of life of the administrative/technical employees of the University of Ferrara and its relationship with sleep quality, chronotype, and family components. PATIENTS AND METHODS We invited all employees (528) to fill a data collection form (age, gender, education level, number of family components, being caregiver and job-related factors) and 3 anonymous questionnaires (VR-12 Health-Related Quality of Life, Pittsburgh Sleep Quality Index, and Morningness-Eveningness Questionnaire). RESULTS Out of 323 respondents, 72.5% were female, 76.4% had an age between 41-60 years old, 63.8% had a university degree, and 67.5% an administrative profile. Considering family-related characteristics: 81.1% of respondents lived with ≥2 people, 35.3% had children, and 31.9% declared to be caregiver of a family member, not necessarily co-housing. Most of the employees resulted to be Morning-type (48.6%) and Intermediate-type (46.8%), with a very limited group of Evening-types (4.6%). Quality of sleep resulted to be the main factor affecting the health-related quality of life. Near half of our sample had poor sleep quality (49.2%; 95% CI: 43.6-54.8%). PSQI score resulted significantly higher for people who were caregivers of a familiar (7.0 ± 3.6 vs. 6.1 ± 3.6, p=0.022). Family size and being caregiver of a familiar resulted in significant factors for sleep quality, and indirectly for health-related quality of life. CONCLUSIONS The quality of sleep is the most influencing parameter of the workers' quality of life. Family size and being caregiver of a family member indirectly affect the quality of life by influencing sleep quality. Appropriate consideration and management of these aspects in the working context could improve workers' well-being.
Collapse
Affiliation(s)
- M Stendardo
- Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
| | | | | | | | | | | |
Collapse
|
15
|
Venanzi M, Savioli M, Cimino R, Gatto E, Palleschi A, Ripani G, Cicero D, Placidi E, Orvieto F, Bianchi E. A spectroscopic and molecular dynamics study on the aggregation process of a long-acting lipidated therapeutic peptide: the case of semaglutide. Soft Matter 2020; 16:10122-10131. [PMID: 32780784 DOI: 10.1039/d0sm01011a] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
The aggregation properties of semaglutide, a lipidated peptide drug agonist of the Glucagon-like peptide 1 receptor recently approved for the treatment of type 2 diabetes, have been investigated by spectroscopic techniques (UV-Vis absorption, steady-state and time-resolved fluorescence, and electronic circular dichroism) and molecular dynamics simulations. We show that in the micromolar concentration region, in aqueous solution, semaglutide is present as monomeric and dimeric species, with a characteristic monomer-to-dimer transition occurring at around 20 μM. The lipid chain stabilizes a globular morphology of the monomer and dimer species, giving rise to a locally well-defined polar outer surface where the lipid and peptide portions are packed to each other. At very long times, these peptide clusters nucleate the growth of larger aggregates characterized by blue luminescence and a β-sheet arrangement of the peptide chains. The understanding of the oligomerization and aggregation potential of peptide candidates is key for the development of long acting and stable drugs.
Collapse
Affiliation(s)
- M Venanzi
- Dept. of Chemical Science and Technologies, University of Rome Tor Vergata, Via Ricerca Scientifica, 1, 00133 Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Moro E, Priori A, Beghi E, Helbok R, Campiglio L, Bassetti CL, Bianchi E, Maia LF, Ozturk S, Cavallieri F, Zedde M, Sellner J, Bereczki D, Rakusa M, Di Liberto G, Sauerbier A, Pisani A, Macerollo A, Soffietti R, Taba P, Crean M, Twardzik A, Oreja-Guevara C, Bodini B, Jenkins TM, von Oertzen TJ. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. Eur J Neurol 2020; 27:1727-1737. [PMID: 32558002 PMCID: PMC7323212 DOI: 10.1111/ene.14407] [Citation(s) in RCA: 69] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 06/08/2020] [Indexed: 12/13/2022]
Abstract
Background and purpose Although the main clinical features of COVID‐19 infection are pulmonary, several associated neurological signs, symptoms and diseases are emerging. The incidence and characteristics of neurological complications are unclear. For this reason, the European Academy of Neurology (EAN) core COVID‐19 Task Force initiated a survey on neurological symptoms observed in patients with COVID‐19 infection. Methods A 17‐question online survey was made available on the EAN website and distributed to EAN members and other worldwide physicians starting on 9 April 2020. Results By 27 April 2020, proper data were collected from 2343 responders (out of 4199), of whom 82.0% were neurologists, mostly from Europe. Most responders (74.7%) consulted patients with COVID‐19 mainly in emergency rooms and in COVID‐19 units. The majority (67.0%) had evaluated fewer than 10 patients with neurological manifestations of COVID‐19 (neuro COVID‐19). The most frequently reported neurological findings were headache (61.9%), myalgia (50.4%), anosmia (49.2%), ageusia (39.8%), impaired consciousness (29.3%) and psychomotor agitation (26.7%). Encephalopathy and acute cerebrovascular disorders were reported at 21.0%. Neurological manifestations were generally interpreted as being possibly related to COVID‐19; they were most commonly recognized in patients with multiple general symptoms and occurred at any time during infection. Conclusion Neurologists are currently and actively involved in the management of neurological issues related to the COVID‐19 pandemic. This survey justifies setting up a prospective registry to better capture the prevalence of patients with neuro COVID‐19, neurological disease characteristics and the contribution of neurological manifestations to outcome.
Collapse
Affiliation(s)
- E Moro
- Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble Institute of Neurosciences, Grenoble, France
| | - A Priori
- Department of Neurology, Division of Neurology, 'Aldo Ravelli' Research Center, University of Milan and ASST Santi Paolo e Carlo, Milan, Italy
| | - E Beghi
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - R Helbok
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - L Campiglio
- Department of Neurology, Division of Neurology, 'Aldo Ravelli' Research Center, University of Milan and ASST Santi Paolo e Carlo, Milan, Italy
| | - C L Bassetti
- Department of Neurology, University of Bern, Inselspital, Bern, Switzerland
| | - E Bianchi
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - L F Maia
- Department of Neurology, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - S Ozturk
- Department of Neurology, Faculty of Medicine, Selcuk University, Konya, Turkey
| | - F Cavallieri
- Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Italy
| | - M Zedde
- Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Italy
| | - J Sellner
- Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.,Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.,Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - D Bereczki
- Department of Neurology, Semmelweis University, Budapest, Hungary
| | - M Rakusa
- Department of Neurology, University Medical Centre Maribor, Maribor, Slovenia
| | - G Di Liberto
- Department of Pathology and Immunology, Geneva Faculty of Medicine, Geneva, Switzerland
| | - A Sauerbier
- Department of Neurology, University Hospital Cologne, Cologne, Germany.,National Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK
| | - A Pisani
- Neurology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - A Macerollo
- Walton Centre NHS Foundation Trust, Liverpool, UK.,School of Psychology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
| | - R Soffietti
- Department of Neuroscience, Division of Neuro-Oncology, University of Turin, Turin, Italy
| | - P Taba
- Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Estonia
| | - M Crean
- European Academy of Neurology, Head Office, Vienna, Austria
| | - A Twardzik
- European Academy of Neurology, Head Office, Vienna, Austria
| | - C Oreja-Guevara
- Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain.,Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain.,IdISSC, Madrid, Spain
| | - B Bodini
- Department of Neurology, Sorbonne University, Saint-Antoine Hospital, APHP, Paris, France
| | - T M Jenkins
- Sheffield Institute for Translational Neuroscience, University of Sheffield, and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - T J von Oertzen
- Department of Neurology 1, Kepler Universitätklinikum, Linz, Austria
| | | |
Collapse
|
17
|
Rosine N, Millot G, Koturan S, Leloup C, Yahia H, Bianchi E, Miceli Richard C, Rogge L. SAT0352 AN UNSUPERVISED ANALYSIS IDENTIFIES A SPECIFIC IMPACT OF BIOLOGICS ON T LYMPHOCYTE PHENOTYPES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:It is currently not known if TNF or IL-17A inhibitors have an impact on immune cell frequencies in axial Spondyloarthritis (AxSpA). This question is important to understand the impact of biologics on the immune system. Data from clinical trials didn’t show significant modification on immune cells and especially on lymphocytes. But regarding the risk of infections linked to these treatments lymphocyte cell subsets are certainly disturbed. Moreover, biologics could affect subsets of cells with an unusual phenotype.Objectives:To identify the phenotype of cell subsets affected by biologics.Methods:We used an “unsupervised approach” to analyze CD4+ T cells and CD8+T cells subsets. Contrary to a “supervised approach”, this strategy takes advantages of the fluorescence emitted by all of the surface markers used to characterize the cells at the same time. The objective was on the one hand to overcome statistical problems related to the number of patients and the repetition of the tests and on the other hand to increase the sensitivity of the analysis by identifying and analyzing new cell populations. The first step was to cluster the cells based on a selection of 12 T cells markers characteristic of the classical cell subsets and the stage of maturation to obtain cell clusters with a phenotype based on the combination of these 12 markers. Then, we were able to describe “a posteriori” the change of frequency of the clusters identified. The second step was to create a visualization of the cells affected to confirm their existence in a classical flow cytometry gate. With this pipeline, we analyzed CD4 and CD8 T cells isolated from a group of AxSpA patients (n=7) before and after 3 months of TNF therapy and a group of patients (n=6) before and after 4 months of IL-17A therapy.Results:We observed that after biologics CD4 and CD8 T cells frequencies did not change but there was a redistribution of the different clusters analyzed. Specifically, we identified for CD4+T cells after anti TNF treatment an increase of 2 clusters (CD4+CD27+CD45RA+Va7.2intCD161int and CD4+CD27-CD45RA-CCR6+CD161int) and a decrease of 3 clusters (CD4+CD27+CD45RA+CRTH2intCD161int, CD4+ CD27+CD45RA+CXCR3+, CD4+CD27+CD45RA+gdint CD161int) and for CD8+T cells a decrease of 1 cluster after treatment (CD8+ CD27+CD45RA+CD161+CXCR3+) and an increase of 1 cluster (CD8+ CD27+CD45RA+). The clusters affected by anti-IL-17A therapy were different. For CD4+T cells, we identified a decrease of 2 clusters (CD4+CD27+CD45RA+CXCR5+ CD161+ and CD4+CD27+CD45RA- CXCR3+CCR6+CD161+) and an increase of 2 clusters (CD4+CD27+CD45RA+gdintCD161+, CD4+CD27+ CRTH2intCCR6+) and for CD8+T cells a decrease of 1 cluster (CD8+CD27+CD45RA+ CXCR3+CRTH2intCD161int) and an increase of 1 cluster (CD8+CD27+CD45RA+CXCR3intCD161-).Conclusion:We identified 5 different clusters in CD4+T cells affected by anti TNF and 4 by anti-IL-17A. We identified 2 clusters in CD8+T cells affected by anti TNF and 2 by anti-IL-17A. The phenotypes of these clusters were unexpected and raised new questions about the effect of biologics in AxSpA. We were also able to create a visualization of these cells affected by biologics in a “classic gating view” which will help us to perform scRNAseq. With this unique approach, we show an impact of biologics on the frequency of very specific subset of CD4+ and CD8+ T cells in AxSpAFigure 1.Disclosure of Interests:None declared
Collapse
|
18
|
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 2020; 135:1859-1869. [PMID: 32267500 DOI: 10.1182/blood.2019003453] [Citation(s) in RCA: 69] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Accepted: 02/12/2020] [Indexed: 02/08/2023] Open
Abstract
Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients with CLL with early, asymptomatic disease (International Prognostic Score for Early-stage CLL [IPS-E]). Individual patient data from 11 international cohorts of patients with early-stage CLL (n = 4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated immunoglobulin heavy variable gene (IGHV), absolute lymphocyte count higher than 15 × 109/L, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (1 point each), and separated low-risk (score 0), intermediate-risk (score 1), and high-risk (score 2-3) patients showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the Binet system and 1 cohort staged by the Rai system. The C-index was 0.74 in the training series and 0.70 in the aggregate of validation series. By meta-analysis of the training and validation cohorts, the 5-year cumulative risk for treatment start was 8.4%, 28.4%, and 61.2% among low-risk, intermediate-risk, and high-risk patients, respectively. The IPS-E is a simple and robust prognostic model that predicts the likelihood of treatment requirement in patients with early-stage CLL. The IPS-E can be useful in clinical management and in the design of early intervention clinical trials.
Collapse
MESH Headings
- Aged
- Biomarkers, Tumor/genetics
- Clinical Trials as Topic/statistics & numerical data
- Combined Modality Therapy
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Male
- Mutation
- Nomograms
- Prognosis
- Retrospective Studies
- Survival Rate
Collapse
Affiliation(s)
- Adalgisa Condoluci
- Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | | | - Petra Langerbeins
- Center of Integrated Oncology Cologne Bonn and German CLL Study Group, University of Cologne, Cologne, Germany
| | | | - Carmen D Herling
- Center of Integrated Oncology Cologne Bonn and German CLL Study Group, University of Cologne, Cologne, Germany
| | - Lorenzo De Paoli
- Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | | | | | | | - Michael Doubek
- Interní Hematologická a Onkologická Klinika (IHOK), University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
- Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | | | - Giorgia Chiodin
- Cancer Sciences Division, University of Southampton, Southampton, United Kingdom
| | | | - Jasmin Bahlo
- Center of Integrated Oncology Cologne Bonn and German CLL Study Group, University of Cologne, Cologne, Germany
| | | | - Jana Kotaskova
- Interní Hematologická a Onkologická Klinika (IHOK), University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
- Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - Clara Deambrogi
- Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | | | - Valeria Spina
- Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland
| | - Alessio Bruscaggin
- Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland
| | - Wei Wu
- Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland
- The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
| | - Riccardo Moia
- Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Elena Bianchi
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Bernhard Gerber
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Emanuele Zucca
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Silke Gillessen
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | | | - Franco Cavalli
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Georg Stussi
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Mark A Hess
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Antonino Neri
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Manlio Ferrarini
- Department of Experimental Medicine, University of Genoa, Genoa, Italy
| | | | - Francesco Forconi
- Cancer Sciences Division, University of Southampton, Southampton, United Kingdom
- Southampton University Hospital Trust, Southampton, United Kingdom
| | - Robin Foà
- Division of Hematology, Sapienza University, Rome, Italy
| | - Sarka Pospisilova
- Interní Hematologická a Onkologická Klinika (IHOK), University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
- Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - Fortunato Morabito
- Biotechnology Research Unit Aprigliano, Cosenza, Italy
- Augusta Victoria Hospital, Jerusalem, Israel
| | - Stephan Stilgenbauer
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; and
| | - Hartmut Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; and
| | | | | | - Emili Montserrat
- Hospital Clinic, Barcelona, Spain
- Institute of Hematology and Oncology, University of Barcelona, Barcelona, Spain
| | - Gianluca Gaidano
- Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - Michael Hallek
- Center of Integrated Oncology Cologne Bonn and German CLL Study Group, University of Cologne, Cologne, Germany
| | - Davide Rossi
- Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| |
Collapse
|
19
|
Borreani C, Alfieri S, Farina L, Bianchi E, Corradini P. Fear of cancer recurrence in haematological cancer patients: exploring socio-demographic, psychological, existential and disease-related factors. Support Care Cancer 2020; 28:5973-5982. [PMID: 32285261 DOI: 10.1007/s00520-020-05434-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Accepted: 03/27/2020] [Indexed: 01/02/2023]
Abstract
PURPOSE This study aims to explore the relation between the dimension of fear of cancer recurrence (FCR) in haematological cancer patients relapse-free for at least 2 years and socio-demographic, related to the disease, psychological and existential factors. METHODS A sample of 75 haematological cancer patients agreed to participate in the study through a self-reported online questionnaire (51.9% males). A total of 70.1% had a low recurrence risk. The questionnaire included socio-demographic (gender, age, civil status, level of education and number of children), related to the disease (diagnosis, therapeutic line and years since diagnosis), psychological (anxiety and depression), existential (purpose in life; PIL) factors and Fear of Cancer Recurrence Concerns Inventory (FCRI). Simple and multiple linear regressions were conducted for the analyses, and we performed some preliminary analysis on the reliability of the FCRI. FINDINGS A total of 53.3% of participants showed clinical levels of FCR on the severity dimension, which was higher than found in previous research in other cancer patients. The coping strategies, triggers, severity and psychological distress dimensions showed higher mean values. Women, patients with indolent non-Hodgkin lymphomas, years since diagnosis, anxiety and purpose in life are significantly related to one or more dimensions of FCRI. IMPLICATIONS It is important that the clinicians have at their disposal multiple possibilities to help patients cope with haematological cancer. If future research will confirm the results of this study, the negative correlation between FCR and PIL can suggest indications for planning interventions based on a salutogenic approach.
Collapse
Affiliation(s)
- C Borreani
- Clinical Psychology Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Via Giacomo Venezian 1, 20133, Milan, Italy
| | - S Alfieri
- Clinical Psychology Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Via Giacomo Venezian 1, 20133, Milan, Italy.
| | - L Farina
- Haematological Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Milan, Italy
| | - E Bianchi
- Clinical Psychology Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Via Giacomo Venezian 1, 20133, Milan, Italy
| | - P Corradini
- Haematological Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Milan, Italy
| |
Collapse
|
20
|
Hurtado P, Prieto M, Martínez-Vilalta J, Giordani P, Aragón G, López-Angulo J, Košuthová A, Merinero S, Díaz-Peña EM, Rosas T, Benesperi R, Bianchi E, Grube M, Mayrhofer H, Nascimbene J, Wedin M, Westberg M, Martínez I. Disentangling functional trait variation and covariation in epiphytic lichens along a continent-wide latitudinal gradient. Proc Biol Sci 2020; 287:20192862. [PMID: 32156209 PMCID: PMC7126072 DOI: 10.1098/rspb.2019.2862] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 02/17/2020] [Indexed: 11/12/2022] Open
Abstract
Characterizing functional trait variation and covariation, and its drivers, is critical to understand the response of species to changing environmental conditions. Evolutionary and environmental factors determine how traits vary among and within species at multiple scales. However, disentangling their relative contribution is challenging and a comprehensive trait-environment framework addressing such questions is missing in lichens. We investigated the variation in nine traits related to photosynthetic performance, water use and nutrient acquisition applying phylogenetic comparative analyses in lichen epiphytic communities on beech across Europe. These poikilohydric organisms offer a valuable model owing to their inherent limitations to buffer contrasting environmental conditions. Photobiont type and growth form captured differences in certain physiological traits whose variation was largely determined by evolutionary processes (i.e. phylogenetic history), although the intraspecific component was non-negligible. Seasonal temperature fluctuations also had an impact on trait variation, while nitrogen content depended on photobiont type rather than nitrogen deposition. The inconsistency of trait covariation among and within species prevented establishing major resource use strategies in lichens. However, we did identify a general pattern related to the water-use strategy. Thus, to robustly unveil lichen responses under different climatic scenarios, it is necessary to incorporate both among and within-species trait variation and covariation.
Collapse
Affiliation(s)
- P. Hurtado
- Área de Biodiversidad y Conservación, Departmento de Biología y Geología, Física y Química Inorgánica, Universidad Rey Juan Carlos, Móstoles, Madrid, Spain
| | - M. Prieto
- Área de Biodiversidad y Conservación, Departmento de Biología y Geología, Física y Química Inorgánica, Universidad Rey Juan Carlos, Móstoles, Madrid, Spain
| | | | | | - G. Aragón
- Área de Biodiversidad y Conservación, Departmento de Biología y Geología, Física y Química Inorgánica, Universidad Rey Juan Carlos, Móstoles, Madrid, Spain
| | - J. López-Angulo
- Área de Biodiversidad y Conservación, Departmento de Biología y Geología, Física y Química Inorgánica, Universidad Rey Juan Carlos, Móstoles, Madrid, Spain
| | - A. Košuthová
- Department of Botany, Swedish Museum of Natural History, Stockholm, Sweden
- Institute of Botany, Plant Science and Biodiversity Center, Slovak Academy of Sciences, Bratislava, Slovak Republic
| | - S. Merinero
- Área de Biodiversidad y Conservación, Departmento de Biología y Geología, Física y Química Inorgánica, Universidad Rey Juan Carlos, Móstoles, Madrid, Spain
- Department of Ecology, Environment and Plant Sciences, Stockholm University, Stockholm, Sweden
| | - E. M. Díaz-Peña
- Área de Biodiversidad y Conservación, Departmento de Biología y Geología, Física y Química Inorgánica, Universidad Rey Juan Carlos, Móstoles, Madrid, Spain
| | - T. Rosas
- CREAF, Bellaterra (Cerdanyola del Valles), Catalonia, Spain
| | - R. Benesperi
- Department of Biology, University of Florence, Firenze, Italy
| | - E. Bianchi
- Department of Biology, University of Florence, Firenze, Italy
| | - M. Grube
- Institute of Biology, Karl-Franzens-Universität Graz, Graz, Austria
| | - H. Mayrhofer
- Institute of Biology, Karl-Franzens-Universität Graz, Graz, Austria
| | - J. Nascimbene
- Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
| | - M. Wedin
- Department of Botany, Swedish Museum of Natural History, Stockholm, Sweden
| | - M. Westberg
- Museum of Evolution, Uppsala University, Uppsala, Sweden
| | - I. Martínez
- Área de Biodiversidad y Conservación, Departmento de Biología y Geología, Física y Química Inorgánica, Universidad Rey Juan Carlos, Móstoles, Madrid, Spain
| |
Collapse
|
21
|
Jedidi Z, Bianchi E, Moonen V, Jedidi H, Serre CH, Maquet P, Moonen G. [Progressive ataxia and falls in a 62 year old woman]. Rev Med Liege 2020; 75:190-198. [PMID: 32157846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
We discuss the diagnostic workup of a 62 year old woman without any significant past medical history. We take this opportunity to point out three aspects : 1. The necessary contextualization of the whole process allowing to avoid unrealistic differentials; 2. The requirement to prioritize the diagnostic tests as a function of their expected contribution to the diagnosis, their invasive characteristic and their availability, including their cost and 3. The evolving character of the diagnostic process that, if needed, has to be reconsidered to integrate the information obtained from the first diagnostic tests and the evolution of the patient.
Collapse
Affiliation(s)
- Z Jedidi
- Service de Neurologie, CHU Liège, Belgique
| | - E Bianchi
- Service d'Anatomopathologie, CHU Liège, Belgique
| | - V Moonen
- Service d'Oto-Rhino-Laryngologie, CHR La Citadelle, Liège, Belgique
| | - H Jedidi
- Service de Neurologie, Clinique du Valdor, Liège, Belgique
| | - C H Serre
- Unité de Soins palliatifs, Clinique du Valdor, Liège, Belgique
| | - P Maquet
- Service de Neurologie, CHU Liège, Belgique
| | - G Moonen
- Faculté de Médecine, ULiège, Belgique
| |
Collapse
|
22
|
Haunschild J, Khachatryan Z, von Aspern K, Bianchi E, Ossmann S, Borger M, Etz C. Impact of CSF Pressure Increase on Spinal Cord Perfusion Simulating Thoracoabdominal Aortic Aneurysm Repair in a Large Animal Model. Thorac Cardiovasc Surg 2020. [DOI: 10.1055/s-0040-1705390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
23
|
von Aspern K, Bianchi E, Haunschild J, Misfeld M, Mohr FW, Borger M, Etz C. Is Concomitant Septal Myectomy during Aortic Valve Replacement Associated with an Increase in Adverse Events? A Single-Center Comparative Study. Thorac Cardiovasc Surg 2020. [DOI: 10.1055/s-0040-1705483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
24
|
Beghi E, Giussani G, Bianchi E, Randazzo G, Sarcona V, Elia M, Striano P, Verrotti A, Ferretti A, Rebessi E, Specchio N, Bonanni P. A validation study of the clinical diagnosis of Dup15q syndrome: Which symptoms matter most? Seizure 2019; 74:26-30. [PMID: 31805494 DOI: 10.1016/j.seizure.2019.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 11/20/2019] [Accepted: 11/22/2019] [Indexed: 10/25/2022] Open
Abstract
PURPOSE Dup15q syndrome is a rare genetic disease with a fairly nonspecific phenotype, clinical heterogeneity, and a wide spectrum of severity. However, no formal characterization has been attempted to select clusters of symptoms, signs and instrumental tests, to be used in the differential diagnosis with other neurodevelopmental disorders. Thus, our purpose was to identify symptoms, signs and instrumental findings, singly or in various combinations, favoring the early diagnosis of the Dup15q syndrome and the indication for genetic testing. METHODS 25 patients with Dup15q syndrome and 25 age and sex matched controls with other neurodevelopmental disorders were the study population. Patients' history, clinical and instrumental assessment were examined by five expert child neurologists blind to the genetic diagnosis. Each rater was asked to make the diagnosis in three subsequent steps: 1. Revision of the medical records; 2. Examination of the videorecorded clinical findings; 3. Assessment of the instrumental tests. Inter-rater agreement was measured with the Kendall's coefficient of concordance) and the Kappa statistic. Sensitivity, specificity and predictive values for symptoms, signs and instrumental findings, singly or in various combinations, were measured. RESULTS The Kendall's coefficient for the diagnosis of Dup15q syndrome was 0.43 at step 1 was 0.43, at step 2 was 0.42, at step 3. Patients with past feeding difficulties, hypotonia during the neonatal period, and epilepsy had >80 % probability of having the Dup15q syndrome. CONCLUSION Feeding difficulties, hypotonia and epilepsy, though unspecific, can be used as signals of Dup15q syndrome and focused search of genetic abnormalities.
Collapse
Affiliation(s)
- E Beghi
- Laboratory of Neurological Disorders, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
| | - G Giussani
- Laboratory of Neurological Disorders, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
| | - E Bianchi
- Laboratory of Neurological Disorders, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
| | - G Randazzo
- Scientific IRCCS E. Medea, San Vito al Tagliamento, Pordenone, Italy
| | - V Sarcona
- Scientific Institute, IRCCS E. Medea, Epilepsy and Clinical Neurophysiology Unit, Conegliano, Treviso, Italy
| | - M Elia
- Oasi Research Institute - IRCCS, Troina, Italy
| | - P Striano
- Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, "G. Gaslini" Institute, Genova, Italy
| | - A Verrotti
- Department of Pediatrics, University of L'Aquila, Italy
| | - A Ferretti
- Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy
| | - E Rebessi
- Pediatric Neurology Unit and Epilepsy Center, Department of Neuroscience, "Fatebenefratelli e Oftalmico'' Hospital, Milano, Italy
| | - N Specchio
- Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy
| | - P Bonanni
- Scientific Institute, IRCCS E. Medea, Epilepsy and Clinical Neurophysiology Unit, Conegliano, Treviso, Italy
| |
Collapse
|
25
|
Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer AJ, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, Stüssi G, Ghilardi G, Gerber B. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematol Oncol 2019; 37:595-600. [DOI: 10.1002/hon.2677] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Revised: 09/01/2019] [Accepted: 09/03/2019] [Indexed: 11/10/2022]
Affiliation(s)
- Rahel Schwotzer
- Department of Medical Oncology and HematologyUniversity and University Hospital Zürich Zürich Switzerland
| | - Markus Gabriel Manz
- Department of Medical Oncology and HematologyUniversity and University Hospital Zürich Zürich Switzerland
| | - Stefanie Pederiva
- Division of Hematology and OncologyKantonsspital Baden Baden Switzerland
| | - Christine Waibel
- Division of Hematology and OncologyKantonsspital Baden Baden Switzerland
| | - Clemens Caspar
- Division of Hematology and OncologyKantonsspital Baden Baden Switzerland
| | - Erika Lerch
- Division of OncologyOncology Institute of Southern Switzerland Bellinzona Switzerland
| | - Andreas J. Flammer
- University Heart CenterUniversity and University Hospital Zürich Zürich Switzerland
| | - Sofie Brouwers
- University Heart CenterUniversity and University Hospital Zürich Zürich Switzerland
| | - Harald Seeger
- Division of NephrologyUniversity and University Hospital Zürich Zürich Switzerland
| | - Raphael Heimgartner
- Department of Internal MedicineCantonal Hospital Graubünden Chur Switzerland
| | - Thomas Fehr
- Department of Internal MedicineCantonal Hospital Graubünden Chur Switzerland
| | - Davide Rossi
- Division of HematologyOncology Institute of Southern Switzerland Bellinzona Switzerland
| | - Elena Bianchi
- Division of HematologyOncology Institute of Southern Switzerland Bellinzona Switzerland
| | - Georg Stüssi
- Division of HematologyOncology Institute of Southern Switzerland Bellinzona Switzerland
| | - Guido Ghilardi
- Division of HematologyOncology Institute of Southern Switzerland Bellinzona Switzerland
| | - Bernhard Gerber
- Division of HematologyOncology Institute of Southern Switzerland Bellinzona Switzerland
| |
Collapse
|
26
|
Gagliardo T, Gandini G, Gallucci A, Menchetti M, Bianchi E, Turba ME, Cauduro A, Corlazzoli DS, Gianni S, Baroni M, Bernardini M, Gentilini F. ABCB1 c.-6-180T>G polymorphism and clinical risk factors in a multi-breed cohort of dogs with refractory idiopathic epilepsy. Vet J 2019; 253:105378. [PMID: 31685133 DOI: 10.1016/j.tvjl.2019.105378] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Revised: 08/19/2019] [Accepted: 09/10/2019] [Indexed: 10/26/2022]
Abstract
Epilepsy is the most common chronic neurological disorder in dogs. Approximately 20-30% of dogs do not achieve satisfactory seizure control with two or more anti-epileptic drugs at appropriate dosages. This condition, defined as refractory epilepsy, is a multifactorial condition involving both acquired and genetic factors. The P glycoprotein might play and important role in the pathophysiological mechanism and it is encoded by the ABCB1 gene. An association between a single nucleotide variation of the ABCB1 gene (c.-6-180T>G) and phenobarbital resistance has previously been reported in a Border collie population with idiopathic epilepsy. To date, the presence and relevance of this polymorphism has not been assessed in other breeds. A multicentre retrospective, case-control study was conducted to investigate associations between ABCB1 c.-6-180T>G, clinical variables, and refractoriness in a multi-breed population of dogs with refractory idiopathic epilepsy. A secondary aim was to evaluate the possible involvement of the ABCB1 c.-6-180T>G single nucleotide variation this population. Fifty-two refractory and 50 responsive dogs with idiopathic epilepsy were enrolled. Of these, 45 refractory and 50 responsive (control) dogs were genotyped. The G allele was found in several breeds, but there was no evidence of association with refractoriness (P=0.69). The uncertain role of the c.-6-180T>G variation was further suggested by an association between the T/T genotype with both refractoriness and responsiveness in different breeds. Furthermore, high seizure density (cluster seizure) was the main clinical risk factor for refractory idiopathic epilepsy (P=0.003).
Collapse
Affiliation(s)
- T Gagliardo
- Department of Veterinary Medical Sciences, University of Bologna, 50 via Tolara di sopra, Ozzano dell'Emilia, BO 40064, Italy.
| | - G Gandini
- Department of Veterinary Medical Sciences, University of Bologna, 50 via Tolara di sopra, Ozzano dell'Emilia, BO 40064, Italy
| | - A Gallucci
- Department of Veterinary Medical Sciences, University of Bologna, 50 via Tolara di sopra, Ozzano dell'Emilia, BO 40064, Italy
| | - M Menchetti
- Department of Veterinary Medical Sciences, University of Bologna, 50 via Tolara di sopra, Ozzano dell'Emilia, BO 40064, Italy
| | - E Bianchi
- Department of Veterinary Medical Sciences, University of Parma, 80 via Tiglio, Parma, PR 43100, Italy
| | - M E Turba
- Genefast, Bologna, 17/d via Castelfranco, Valsamoggia, BO 40053, Italy
| | - A Cauduro
- Neurovet Professional Association, 29 via Maestri del lavoro, Legnano, MI 20025, Italy
| | - D S Corlazzoli
- Roma Sud Veterinary Clinic, 24 via Pilade Mazza, Rome, RM 00173, Italy
| | - S Gianni
- Gran Sasso Veterinary Clinic, 26 via Donatello, Milan, MI 20131, Italy
| | - M Baroni
- Valdinievole Veterinary Hospital, 123 via Nigra Costantino, Monsummano Terme, PT 51015, Italy
| | - M Bernardini
- Portoni Rossi Veterinary Hospital, 57/a via Roma, Zola Predosa, BO 40069, Italy
| | - F Gentilini
- Department of Veterinary Medical Sciences, University of Bologna, 50 via Tolara di sopra, Ozzano dell'Emilia, BO 40064, Italy
| |
Collapse
|
27
|
Doneddu PE, Bianchi E, Cocito D, Manganelli F, Fazio R, Filosto M, Mazzeo A, Cosentino G, Cortese A, Jann S, Clerici AM, Antonini G, Siciliano G, Luigetti M, Marfia GA, Briani C, Lauria G, Rosso T, Cavaletti G, Carpo M, Benedetti L, Beghi E, Liberatore G, Santoro L, Peci E, Tronci S, Cotti Piccinelli S, Toscano A, Piccolo L, Verrengia EP, Leonardi L, Schirinzi E, Mataluni G, Ruiz M, Dacci P, Nobile‐Orazio E. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. Eur J Neurol 2019; 27:136-143. [DOI: 10.1111/ene.14044] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Accepted: 07/10/2019] [Indexed: 02/06/2023]
Affiliation(s)
- P. E. Doneddu
- Humanitas Clinical and Research Institute MilanItaly
| | | | | | | | - R. Fazio
- San Raffaele Scientific Institute MilanItaly
| | - M. Filosto
- ASST ‘Spedali Civili’ University of Brescia BresciaItaly
| | | | | | - A. Cortese
- IRCCS Foundation C. Mondino National Neurological Institute PaviaItaly
| | - S. Jann
- Niguarda Ca’ Granda Hospital MilanItaly
| | - A. M. Clerici
- Circolo and Macchi Foundation Hospital Insubria UniversityDBSV VareseItaly
| | - G. Antonini
- ‘Sapienza’ University of RomeSant'Andrea Hospital RomeItaly
| | | | - M. Luigetti
- Catholic University of Sacred Heart RomeItaly
| | | | | | - G. Lauria
- IRCCS Foundation ‘Carlo Besta’ Neurological Institute University of Milan MilanItaly
| | - T. Rosso
- UOC Neurologia‐Castelfranco Veneto TrevisoItaly
| | | | - M. Carpo
- ASST Bergamo Ovest‐Ospedale Treviglio TreviglioItaly
| | | | - E. Beghi
- Istituto Mario Negri IRCCS MilanItaly
| | - G. Liberatore
- Humanitas Clinical and Research Institute MilanItaly
| | - L. Santoro
- University of Naples ‘Federico II’ NaplesItaly
| | - E. Peci
- University of Turin TurinItaly
| | - S. Tronci
- San Raffaele Scientific Institute MilanItaly
| | | | | | - L. Piccolo
- IRCCS Foundation C. Mondino National Neurological Institute PaviaItaly
| | | | - L. Leonardi
- ‘Sapienza’ University of RomeSant'Andrea Hospital RomeItaly
| | | | | | - M. Ruiz
- University of Padua PaduaItaly
| | - P. Dacci
- IRCCS Foundation ‘Carlo Besta’ Neurological Institute University of Milan MilanItaly
| | - E. Nobile‐Orazio
- Humanitas Clinical and Research Institute MilanItaly
- Milan University Milan Italy
| | | |
Collapse
|
28
|
Sceberras V, Attico E, Bianchi E, Galaverni G, Melonari M, Corradini F, Fantacci M, Ribbene A, Losi L, Balò S, Lazzeri M, Trombetta C, Rizzo M, Manfredini R, Barbagli G, Pellegrini G. Preclinical study for treatment of hypospadias by advanced therapy medicinal products. World J Urol 2019; 38:2115-2122. [PMID: 31289843 DOI: 10.1007/s00345-019-02864-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Accepted: 06/27/2019] [Indexed: 02/03/2023] Open
Abstract
PURPOSE This paper explores the feasibility of a new therapy for the treatment of hypospadias patients. Hypospadias is a very common congenital malformation of male genitals, with very high rate of recurrences after surgery. The field of regenerative medicine, which offers innovative solutions for many pathologies, still does not offer reliable solution for this pathology. Here, we propose quality, safety, and clinical feasibility assessment for an oral mucosa advanced therapy medicinal product (ATMP) grown on a biocompatible scaffold for a clinical study on urethral reconstruction of hypospadias patients. METHODS Urethral and oral mucosal epithelia from donor biopsies were cultivated between two fibrin layers, under clinical-grade conditions for cell and tissue characterization and comparison, aimed at tissue engineering. In addition, single-clone analyses were performed to analyze gene expression profiles of the two epithelia by microarray technology. RESULTS Oral mucosa appeared suitable for urethral reconstruction. The resulting ATMP was proven to maintain stem cells and regenerative potency. The preclinical safety studies were performed on human tissues to assess abnormalities and tumorigenicity, and confirmed the safety of the ATMP. Finally, the patient selection and the clinical protocol for the upcoming clinical trial were defined. CONCLUSIONS Against this backdrop, in this paper, we are proposing a new reproducible and reliable ATMP for the treatment of hypospadias.
Collapse
Affiliation(s)
- V Sceberras
- Holostem Terapie Avanzate, Via Gottardi 100, Modena, Italy
| | - E Attico
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy
| | - E Bianchi
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy
| | - G Galaverni
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy
| | - M Melonari
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy
| | - F Corradini
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy
| | - M Fantacci
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy
| | - A Ribbene
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy
| | - L Losi
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy
| | - S Balò
- Centro Chirurgico Toscano, Via dei Lecci 22, Arezzo, Italy
| | - M Lazzeri
- Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital (MI), Rozzano, Italy
| | - C Trombetta
- Department of Urology of Cattinara Hospital, University of Trieste, Strada Fiume 447, Trieste, Italy
| | - M Rizzo
- Department of Urology of Cattinara Hospital, University of Trieste, Strada Fiume 447, Trieste, Italy
| | - R Manfredini
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy
| | - G Barbagli
- Centro Chirurgico Toscano, Via dei Lecci 22, Arezzo, Italy
| | - G Pellegrini
- Interdepartmental Centre for Regenerative Medicine "Stefano Ferrari", University of Modena e Reggio Emilia, Via Gottardi 100, Modena, Italy. .,Holostem Terapie Avanzate, Via Gottardi 100, Modena, Italy.
| |
Collapse
|
29
|
Monteiro BP, Lambert C, Bianchi E, Genevois JP, Soldani G, Troncy E. Safety and efficacy of reduced dosage ketoprofen with or without tramadol for long-term treatment of osteoarthritis in dogs: a randomized clinical trial. BMC Vet Res 2019; 15:213. [PMID: 31238912 PMCID: PMC6591828 DOI: 10.1186/s12917-019-1960-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Accepted: 06/13/2019] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND This study aimed to evaluate the safety and efficacy of reduced-dosage ketoprofen with or without tramadol in dogs. Five healthy dogs receiving standard-dosage ketoprofen (2 mg/kg SC, then 1 mg/kg PO daily) comprised Group A. Twenty dogs with osteoarthritis were randomized to receive reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily) alone (Group B) or in combination with tramadol (5 mg/kg/day PO) (Group C). Treatments were administered for 28 days. Platelet aggregation time (PAT), gastrointestinal (GI) endoscopy and glomerular filtration rate (GFR) were performed up to 60 days after treatment initiation. Pain was scored using a validated clinical metrology instrument up to D120. Data were analyzed with general linear mixed model for repeated measures (α = 0.05). RESULTS PAT was not different between groups but was increased with time for all groups. GI lesion scores were higher in Group A than Groups B and C (day 28; P = 0.005) and were increased with time for Group A (P = 0.005). GFR was lower in Group A than Groups B and C (day 28; P < 0.01) and were decreased with time for group A (P < 0.001). Standard-dosage ketoprofen administration resulted in clinically relevant adverse effects. Pain score decreased in both treated groups (B and C) from D0 to D28. Need of rescue analgesia from D29 to D120 was higher in Group B than in Group C (P = 0.039). CONCLUSIONS The long-term safety profile of reduced-dosage ketoprofen is similar whether the drug is administered alone or in combination with tramadol to dogs with osteoarthritis. Analgesic efficacy of the combination looks attractive.
Collapse
Affiliation(s)
- Beatriz P Monteiro
- Department of Biomedical Sciences, GREPAQ (Groupe de recherche en pharmacologie animale du Québec), Faculty of Veterinary Medicine - Université de Montréal, 3200 Sicotte Street, Saint-Hyacinthe, QC, J2S 2M2, Canada
| | - Cedric Lambert
- Department of Companion Animals, Vet-Agro Sup, Lyon, France
| | - Elena Bianchi
- Department of Pharmacology, College of Veterinary Medicine, University of Pisa, Pisa, Italy
| | | | - Giulio Soldani
- Department of Pharmacology, College of Veterinary Medicine, University of Pisa, Pisa, Italy
| | - Eric Troncy
- Department of Biomedical Sciences, GREPAQ (Groupe de recherche en pharmacologie animale du Québec), Faculty of Veterinary Medicine - Université de Montréal, 3200 Sicotte Street, Saint-Hyacinthe, QC, J2S 2M2, Canada.
| |
Collapse
|
30
|
Giusti A, Bianchi E, Barontini F, Cripezzi M, Tasselli G, Armani A. Data analysis of official checks on intra-EU seafood trade: A survey on the Italian veterinary office for compliance with EU requirement (UVAC) of Tuscany in three-year period 2014–2016. Food Control 2019. [DOI: 10.1016/j.foodcont.2018.08.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
31
|
Lefloch B, Bachiller R, Ceccarelli C, Cernicharo J, Codella C, Fuente A, Kahane C, López-Sepulcre A, Tafalla M, Vastel C, Caux E, González-García M, Bianchi E, Gómez-Ruiz A, Holdship J, Mendoza E, Ospina-Zamudio J, Podio L, Quénard D, Roueff E, Sakai N, Viti S, Yamamoto S, Yoshida K, Favre C, Monfredini T, Quitián-Lara HM, Marcelino N, Boechat-Roberty HM, Cabrit S. Astrochemical evolution along star formation: Overview of the IRAM Large Program ASAI. Mon Not R Astron Soc 2018; 477:4792-4809. [PMID: 30197453 PMCID: PMC6126616 DOI: 10.1093/mnras/sty937] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Evidence is mounting that the small bodies of our Solar System, such as comets and asteroids, have at least partially inherited their chemical composition from the first phases of the Solar System formation. It then appears that the molecular complexity of these small bodies is most likely related to the earliest stages of star formation. It is therefore important to characterize and to understand how the chemical evolution changes with solar-type protostellar evolution. We present here the Large Program "Astrochemical Surveys At IRAM" (ASAI). Its goal is to carry out unbiased millimeter line surveys between 80 and 272 GHz of a sample of ten template sources, which fully cover the first stages of the formation process of solar-type stars, from prestellar cores to the late protostellar phase. In this article, we present an overview of the surveys and results obtained from the analysis of the 3 mm band observations. The number of detected main isotopic species barely varies with the evolutionary stage and is found to be very similar to that of massive star-forming regions. The molecular content in O- and C- bearing species allows us to define two chemical classes of envelopes, whose composition is dominated by either a) a rich content in O-rich complex organic molecules, associated with hot corino sources, or b) a rich content in hydrocarbons, typical of Warm Carbon Chain Chemistry sources. Overall, a high chemical richness is found to be present already in the initial phases of solar-type star formation.
Collapse
Affiliation(s)
- Bertrand Lefloch
- CNRS, IPAG, Univ. Grenoble Alpes, F-38000 Grenoble, France
- IAG, Universidade de São Paulo, Cidade Universitária, SP 05508-090, Brazil
| | - R Bachiller
- IGN Observatorio Astronómico Nacional, Apartado 1143, 28800 Alcalá de Henares, Spain
| | - C Ceccarelli
- CNRS, IPAG, Univ. Grenoble Alpes, F-38000 Grenoble, France
| | - J Cernicharo
- Group of Molecular Astrophysics, ICMM, CSIC, C/Sor Juana Inés de La Cruz N3, E-28049, Madrid, Spain
| | - C Codella
- INAF, Osservatorio Astrofisico di Arcetri, Largo Enrico Fermi 5, I-50125 Firenze, Italy
| | - A Fuente
- IGN Observatorio Astronómico Nacional, Apartado 1143, 28800 Alcalá de Henares, Spain
| | - C Kahane
- CNRS, IPAG, Univ. Grenoble Alpes, F-38000 Grenoble, France
| | - A López-Sepulcre
- IRAM, 300 rue de la Piscine, 38406 Saint-Martin d' Hères, France
- CNRS, IPAG, Univ. Grenoble Alpes, F-38000 Grenoble, France
| | - M Tafalla
- IGN Observatorio Astronómico Nacional, Apartado 1143, 28800 Alcalá de Henares, Spain
| | - C Vastel
- Université de Toulouse, UPS-OMP, IRAP, Toulouse, France
| | - E Caux
- Université de Toulouse, UPS-OMP, IRAP, Toulouse, France
| | - M González-García
- IGN Observatorio Astronómico Nacional, Apartado 1143, 28800 Alcalá de Henares, Spain
- Group of Molecular Astrophysics, ICMM, CSIC, C/Sor Juana Inés de La Cruz N3, E-28049, Madrid, Spain
| | - E Bianchi
- INAF, Osservatorio Astrofisico di Arcetri, Largo Enrico Fermi 5, I-50125 Firenze, Italy
- Università degli Studi di Firenze, Dipartimento di Fisica e Astronomia, Via G. Sansone 1, I-50019 Sesto Fiorentino, Italy
| | - A Gómez-Ruiz
- CONACYT-Instituto Nacional de Astrofísica, Optica y Electrónica, Luis E. Erro 1, 72840 Tonantzintla, Puebla, México
- INAF, Osservatorio Astrofisico di Arcetri, Largo Enrico Fermi 5, I-50125 Firenze, Italy
| | - J Holdship
- Department of Physics and Astronomy, UCL, Gower St., London, WC1E 6BT, UK
| | - E Mendoza
- IAG, Universidade de São Paulo, Cidade Universitária, SP 05508-090, Brazil
| | | | - L Podio
- INAF, Osservatorio Astrofisico di Arcetri, Largo Enrico Fermi 5, I-50125 Firenze, Italy
| | - D Quénard
- Department of Physics and Astronomy, UCL, Gower St., London, WC1E 6BT, UK
| | - E Roueff
- Sorbonne Université, Observatoire de Paris, Université PSL, CNRS, LERMA, F-92190, Meudon, France
| | - N Sakai
- The Institute of Physical and Chemical Research (RIKEN), Wako, Saitama 351-0198, Japan
| | - S Viti
- Department of Physics and Astronomy, UCL, Gower St., London, WC1E 6BT, UK
| | - S Yamamoto
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - K Yoshida
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - C Favre
- INAF, Osservatorio Astrofisico di Arcetri, Largo Enrico Fermi 5, I-50125 Firenze, Italy
| | - T Monfredini
- Observatorio do Valongo, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 20080-090, Brasil
| | - H M Quitián-Lara
- Observatorio do Valongo, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 20080-090, Brasil
| | - N Marcelino
- Group of Molecular Astrophysics, ICMM, CSIC, C/Sor Juana Inés de La Cruz N3, E-28049, Madrid, Spain
| | - H M Boechat-Roberty
- Observatorio do Valongo, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 20080-090, Brasil
| | - S Cabrit
- Sorbonne Université, Observatoire de Paris, Université PSL, CNRS, LERMA, F-75014 Paris, France
| |
Collapse
|
32
|
Bianchi E, Stermer A, Boekelheide K, Sigman M, Hall SJ, Reyes G, Dere E, Hwang K. High-quality human and rat spermatozoal RNA isolation for functional genomic studies. Andrology 2018; 6:374-383. [PMID: 29470852 DOI: 10.1111/andr.12471] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 12/11/2017] [Accepted: 01/04/2018] [Indexed: 12/30/2022]
Abstract
Sperm RNA is a sensitive monitoring endpoint for male reproductive toxicants, and a potential biomarker to assess male infertility and sperm quality. However, isolation of sperm RNA is a challenging procedure due to the heterogeneous population of cells present in the ejaculate, the low yield of RNA per spermatozoon, and the absence of 18S and 28S ribosomal RNA subunits. The unique biology of spermatozoa has created some uncertainty in the field about RNA isolation methods, indicating the need for rigorous quality control checks to ensure reproducibility of data generated from sperm RNA. Therefore, we developed a reliable and effective protocol for RNA isolation from rat and human spermatozoa that delivers highly purified and intact RNA, verified using RNA-specific electrophoretic chips and molecular biology approaches such as RT-PCR and Western blot analysis. The sperm RNA isolation technique was optimized using rat spermatozoa and then adapted to human spermatozoa. Three steps in the sperm isolation procedure, epididymal fluid collection, sperm purification, and spermatozoon RNA extraction, were evaluated and assessed. The sperm RNA extraction methodology consists of collection of rat epididymal fluid with repeated needle punctures of the epididymis, somatic cell elimination using detergent-based somatic cell lysis buffer (SCLB) and the use of RNA isolation Kit. Rat sperm heads are more resistant to disruption than human spermatozoa, necessitating the addition of mechanical lysis with microbeads and heat in the rat protocol, whereas the human sperm protocol only required lysis buffer. In conclusion, this methodology results in reliable and consistent isolation of high-quality sperm RNA. Using this technique will aid in translation of data collected from animal models, and reproducibility of clinical assessment of male factor fertility using RNA molecular biomarkers.
Collapse
Affiliation(s)
- E Bianchi
- Division of Urology, Rhode Island Hospital, Providence, RI, USA.,Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA
| | - A Stermer
- Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA
| | - K Boekelheide
- Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA
| | - M Sigman
- Division of Urology, Rhode Island Hospital, Providence, RI, USA.,Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA
| | - S J Hall
- Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA
| | - G Reyes
- Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA
| | - E Dere
- Division of Urology, Rhode Island Hospital, Providence, RI, USA.,Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA
| | - K Hwang
- Division of Urology, Rhode Island Hospital, Providence, RI, USA.,Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA
| |
Collapse
|
33
|
Brunelli C, Pigni A, Mandelli C, Bianchi E, Ferrigato L, Broglia M, Nanni O, Dall'Agata M, Sansoni E, Cavanna L, Dadduzio V, Garetto F, Pino M, Bortolussi R, Luzzani M, Giaretto L, Perfetti E, Autelitano C, Piga M, Caraceni A. Quality of end of life care in patients with pancreatic cancer receiving systematic versus on-demand early palliative care at diagnosis: a secondary outcome analysis from a randomized controlled trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx435.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Bianchi E, Fantini M, Nicoletti S, Drudi F, Tamburini E, Cherubini C, Ridolfi C, Montanari F, Venturi A, Pasini G, Tassinari D. Enzalutamide (E) vs abiraterone acetate (AA) in the treatment of metastatic, castration-resistant prostate cancer. Indirect comparisons and network meta-analysis for clinical practice. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx423.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Gallucci A, Gagliardo T, Menchetti M, Bianchi E, Bucci D, Gandini G. Long-term efficacy of imepitoin in the treatment of naive dogs affected by idiopathic epilepsy. Vet Rec 2017; 181:144. [DOI: 10.1136/vr.104187] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/07/2017] [Indexed: 01/21/2023]
Affiliation(s)
- A. Gallucci
- Department of Veterinary Medical Sciences; University of Bologna; Ozzano Emilia Italy
| | - T. Gagliardo
- Department of Veterinary Medical Sciences; University of Bologna; Ozzano Emilia Italy
| | - M. Menchetti
- Department of Veterinary Medical Sciences; University of Bologna; Ozzano Emilia Italy
| | - E. Bianchi
- Department of Veterinary Medical Sciences; University of Parma; Parma Italy
| | - D. Bucci
- Department of Veterinary Medical Sciences; University of Bologna; Ozzano Emilia Italy
| | - G. Gandini
- Department of Veterinary Medical Sciences; University of Bologna; Ozzano Emilia Italy
| |
Collapse
|
36
|
Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia 2017; 32:438-449. [PMID: 28745329 PMCID: PMC5808097 DOI: 10.1038/leu.2017.220] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 06/16/2017] [Accepted: 06/26/2017] [Indexed: 01/13/2023]
Abstract
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by hyperplastic megakaryopoiesis and myelofibrosis. We recently described the upregulation of MAF (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog) in PMF CD34+ hematopoietic progenitor cells (HPCs) compared to healthy donor. Here we demonstrated that MAF is also upregulated in PMF compared with the essential thrombocytemia (ET) and polycytemia vera (PV) HPCs. MAF overexpression and knockdown experiments shed some light into the role of MAF in PMF pathogenesis, by demonstrating that MAF favors the megakaryocyte and monocyte/macrophage commitment of HPCs and leads to the increased expression of proinflammatory and profibrotic mediators. Among them, we focused our further studies on SPP1 and LGALS3. We assessed SPP1 and LGALS3 protein levels in 115 PMF, 47 ET and 24 PV patients plasma samples and we found that SPP1 plasma levels are significantly higher in PMF compared with ET and PV patients. Furthermore, in vitro assays demonstrated that SPP1 promotes fibroblasts and mesenchymal stromal cells proliferation and collagen production. Strikingly, clinical correlation analyses uncovered that higher SPP1 plasma levels in PMF patients correlate with a more severe fibrosis degree and a shorter overall survival. Collectively our data unveil that MAF overexpression contributes to PMF pathogenesis by driving the deranged production of the profibrotic mediator SPP1.
Collapse
Affiliation(s)
- S Ruberti
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - E Bianchi
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - P Guglielmelli
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
| | - S Rontauroli
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - G Barbieri
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - L Tavernari
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - T Fanelli
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
| | - R Norfo
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy.,Haematopoietic Stem Cell Biology Laboratory, MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - V Pennucci
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - G Corbizi Fattori
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.,GenOMec, University of Siena, Siena, Italy
| | - C Mannarelli
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.,GenOMec, University of Siena, Siena, Italy
| | - N Bartalucci
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
| | - B Mora
- Division of Hematology, Ospedale ASST Sette Laghi, Universita degli Studi dell'Insubria, Varese, Italy
| | - L Elli
- Division of Hematology, Ospedale ASST Sette Laghi, Universita degli Studi dell'Insubria, Varese, Italy
| | - M A Avanzini
- Department of Pediatric Onco-Hematology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
| | - C Rossi
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - S Salmoiraghi
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - R Zini
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - S Salati
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - Z Prudente
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| | - V Rosti
- Center for the Study of Myelofibrosis, Foundation IRCCS Policlinico San Matteo, Pavia, Italy
| | - F Passamonti
- Division of Hematology, Ospedale ASST Sette Laghi, Universita degli Studi dell'Insubria, Varese, Italy
| | - A Rambaldi
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - S Ferrari
- Department of Life Sciences, Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy
| | - E Tagliafico
- Department of Life Sciences, Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy
| | - A M Vannucchi
- Department of Experimental and Clinical Medicine, CRIMM, Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy
| | - R Manfredini
- Department of Life Sciences, Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
37
|
Tresoldi C, Bianchi E, Pellegata AF, Dubini G, Mantero S. Estimation of the physiological mechanical conditioning in vascular tissue engineering by a predictive fluid-structure interaction approach. Comput Methods Biomech Biomed Engin 2017; 20:1077-1088. [DOI: 10.1080/10255842.2017.1332192] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Claudia Tresoldi
- Department of Chemistry, Materials, and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Milan, Italy
| | - Elena Bianchi
- Department of Chemistry, Materials, and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Milan, Italy
| | - Alessandro Filippo Pellegata
- Department of Chemistry, Materials, and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Milan, Italy
| | - Gabriele Dubini
- Department of Chemistry, Materials, and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Milan, Italy
| | - Sara Mantero
- Department of Chemistry, Materials, and Chemical Engineering ‘Giulio Natta’, Politecnico di Milano, Milan, Italy
| |
Collapse
|
38
|
|
39
|
|
40
|
Enomoto J, Kageyama T, Osaki T, Bonalumi F, Marchese F, Gautieri A, Bianchi E, Dubini G, Arrigoni C, Moretti M, Fukuda J. Catch-and-Release of Target Cells Using Aptamer-Conjugated Electroactive Zwitterionic Oligopeptide SAM. Sci Rep 2017; 7:43375. [PMID: 28266533 PMCID: PMC5339905 DOI: 10.1038/srep43375] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Accepted: 01/23/2017] [Indexed: 11/18/2022] Open
Abstract
Nucleic acid aptamers possess attractive features such as specific molecular recognition, high-affinity binding, and rapid acquisition and replication, which could be feasible components for separating specific cells from other cell types. This study demonstrates that aptamers conjugated to an oligopeptide self-assembled monolayer (SAM) can be used to selectively trap human hepatic cancer cells from cell mixtures containing normal human hepatocytes or human fibroblasts. Molecular dynamics calculations have been performed to understand how the configurations of the aptamers are related to the experimental results of selective cell capture. We further demonstrate that the captured hepatic cancer cells can be detached and collected along with electrochemical desorption of the oligopeptide SAM, and by repeating these catch-and-release processes, target cells can be enriched. This combination of capture with aptamers and detachment with electrochemical reactions is a promising tool in various research fields ranging from basic cancer research to tissue engineering applications.
Collapse
Affiliation(s)
- Junko Enomoto
- Graduate School of Engineering, Yokohama National University, Japan
| | - Tatsuto Kageyama
- Graduate School of Engineering, Yokohama National University, Japan
| | - Tatsuya Osaki
- Graduate School of Engineering, Yokohama National University, Japan
| | - Flavia Bonalumi
- Department of Electronics, Information and Bioengineering, Politecnico di Milano, Italy
| | - Francesca Marchese
- Department of Electronics, Information and Bioengineering, Politecnico di Milano, Italy
| | - Alfonso Gautieri
- Department of Electronics, Information and Bioengineering, Politecnico di Milano, Italy
| | - Elena Bianchi
- Department of Chemistry, Politecnico di Milan, Italy
| | | | - Chiara Arrigoni
- Cell and Tissue Engineering Laboratory, IRCCS Galeazzi Orthopaedic Institute, Italy
| | - Matteo Moretti
- Cell and Tissue Engineering Laboratory, IRCCS Galeazzi Orthopaedic Institute, Italy
- Regenerative Medicine Technologies Lab, Ente Ospedaliero Cantonale, Switzerland
- Swiss Institute for Regenerative Medicine, Switzerland
- Cardiocentro Ticino, Switzerland
| | - Junji Fukuda
- Graduate School of Engineering, Yokohama National University, Japan
| |
Collapse
|
41
|
Rollo E, Tenaglia E, Genolet R, Bianchi E, Harari A, Coukos G, Guiducci C. Label-free identification of activated T lymphocytes through tridimensional microsensors on chip. Biosens Bioelectron 2017; 94:193-199. [PMID: 28284079 DOI: 10.1016/j.bios.2017.02.047] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2016] [Revised: 02/15/2017] [Accepted: 02/28/2017] [Indexed: 11/25/2022]
Abstract
Label-free approaches to assess cell properties ideally suit the requirements of cell-based therapeutics, since they permit to characterize cells with minimal perturbation and manipulation, at the benefit of sample recovery and re-employment for treatment. For this reason, label-free techniques would find sensible application in adoptive T cell-based immunotherapy. In this work, we describe the label-free and single-cell detection of in vitro activated T lymphocytes in flow through an electrical impedance-based setup. We describe a novel platform featuring 3D free-standing microelectrodes presenting passive upstream and downstream extensions and integrated into microfluidic channels. We employ such device to measure the impedance change associated with T cell activation at electrical frequencies maximizing the difference between non-activated and activated T cells. Finally, we harness the impedance signature of unstimulated T cells to set a boundary separating activated and non-activated clones, so to characterize the selectivity and specificity of the system. In conclusion, the strategy here proposed highlights the possible employment of impedance to assess T cell activation in label-free.
Collapse
Affiliation(s)
- Enrica Rollo
- Laboratory of Life Sciences Electronics - Swiss Federal Institute of Technology (EPFL), Lausanne CH-1015, Switzerland
| | - Enrico Tenaglia
- Laboratory of Life Sciences Electronics - Swiss Federal Institute of Technology (EPFL), Lausanne CH-1015, Switzerland
| | - Raphaël Genolet
- Ludwig Center for Cancer Research - University of Lausanne (UNIL), CH-1066, Switzerland
| | - Elena Bianchi
- CMIC "Giulio Natta", LaBS - Laboratory of Biological Structure Mechanics - Politecnico di Milano, I-20133, Italy
| | - Alexandre Harari
- Ludwig Center for Cancer Research - University of Lausanne (UNIL), CH-1066, Switzerland
| | - George Coukos
- Ludwig Center for Cancer Research - University of Lausanne (UNIL), CH-1066, Switzerland
| | - Carlotta Guiducci
- Laboratory of Life Sciences Electronics - Swiss Federal Institute of Technology (EPFL), Lausanne CH-1015, Switzerland.
| |
Collapse
|
42
|
Campos Marin A, Grossi T, Bianchi E, Dubini G, Lacroix D. 2D µ-Particle Image Velocimetry and Computational Fluid Dynamics Study Within a 3D Porous Scaffold. Ann Biomed Eng 2016; 45:1341-1351. [PMID: 27957607 PMCID: PMC5397455 DOI: 10.1007/s10439-016-1772-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Accepted: 12/02/2016] [Indexed: 01/14/2023]
Abstract
Transport properties of 3D scaffolds under fluid flow are critical for tissue development. Computational fluid dynamics (CFD) models can resolve 3D flows and nutrient concentrations in bioreactors at the scaffold-pore scale with high resolution. However, CFD models can be formulated based on assumptions and simplifications. μ-Particle image velocimetry (PIV) measurements should be performed to improve the reliability and predictive power of such models. Nevertheless, measuring fluid flow velocities within 3D scaffolds is challenging. The aim of this study was to develop a μPIV approach to allow the extraction of velocity fields from a 3D additive manufacturing scaffold using a conventional 2D μPIV system. The μ-computed tomography scaffold geometry was included in a CFD model where perfusion conditions were simulated. Good agreement was found between velocity profiles from measurements and computational results. Maximum velocities were found at the centre of the pore using both techniques with a difference of 12% which was expected according to the accuracy of the μPIV system. However, significant differences in terms of velocity magnitude were found near scaffold substrate due to scaffold brightness which affected the μPIV measurements. As a result, the limitations of the μPIV system only permits a partial validation of the CFD model. Nevertheless, the combination of both techniques allowed a detailed description of velocity maps within a 3D scaffold which is crucial to determine the optimal cell and nutrient transport properties.
Collapse
Affiliation(s)
- A Campos Marin
- Insigneo Institute for in silico Medicine, Department of Mechanical Engineering, University of Sheffield, Pam Liversidge Building, Mappin Street, Sheffield, S1 3JD, UK
| | - T Grossi
- Laboratory of Biological Structure Mechanics, Politecnico di Milano, Milan, Italy
| | - E Bianchi
- Laboratory of Biological Structure Mechanics, Politecnico di Milano, Milan, Italy
| | - G Dubini
- Laboratory of Biological Structure Mechanics, Politecnico di Milano, Milan, Italy
| | - D Lacroix
- Insigneo Institute for in silico Medicine, Department of Mechanical Engineering, University of Sheffield, Pam Liversidge Building, Mappin Street, Sheffield, S1 3JD, UK.
| |
Collapse
|
43
|
Conteduca V, Casadio V, Caroli P, Scarpi E, Lolli C, Menna C, Bianchi E, Schepisi G, Testoni S, Gurioli G, Salvi S, Amadori D, Paganelli G, Matteucci F, Attard G, De Giorgi U. Increased choline uptake in androgen receptor (AR) copy number gain castration-resistant prostate cancers (CRPC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Agli LL, Cherubini C, Papi M, Santelmo C, Nicoletti S, Bianchi E, Fantini M, Ridolfi C, Stocchi L, Tamburini E, Tassinari D. Cisplatin-raltitrexed vs cisplatin-pemetrexed in the treatment of advanced pleural mesothelioma. Final results of a network meta-analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw391.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Cherubini C, Bianchi E, Tamburini E, Drudi F, Stocchi L, Nicoletti S, Perini F, Venturi A, Montanari F, Tassinari D. Treatment options in advanced castration-resistant, docetaxel-resistant prostate cancer (ACRDRPC). Final results of a network meta-analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Bianchi E, Boekelheide K, Sigman M, Hall S, Hwang K. Molecular mechanisms behind ghrelin-mediated prevention of post-surgical adhesions. Fertil Steril 2016. [DOI: 10.1016/j.fertnstert.2016.07.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
47
|
Cherubini C, Bianchi E, Montanari F, Tamburini E, Fantini M, Ridolfi C, Santelmo C, Nicoletti S, Pasini G, Stocchi L, Tassinari D. Treament options in advanced castration-resistant, docetaxel-resistant prostate cancer (acrdrpc). final results of a network meta-analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw334.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Razza S, Heidig T, Bianchi E, Groppi G, Schwieger W, Tronconi E, Freund H. Heat transfer performance of structured catalytic reactors packed with metal foam supports: Influence of wall coupling. Catal Today 2016. [DOI: 10.1016/j.cattod.2016.02.058] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
49
|
Bianchi E, Bosisio M, Capri G, Mariani P, Miceli R, Borreani C. The psychological consequences after adjuvant aromatase inhibitor therapy in breast cancer women. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw342.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Bianchi E, Cherubini C, Nicoletti S, Fantini M, Drudi F, Arcangeli V, Santelmo C, Montanari F, Venturi A, Nicoletti S, Stocchi L, Tassinari D. Treament options in advanced castration-resistant, prostate cancer (acrpc). preliminary results of a network meta-analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw334.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|